SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-000067
Filing Date
2022-01-04
Accepted
2022-01-04 16:22:52
Documents
12
Period of Report
2021-12-31
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_123121.htm   iXBRL 8-K 26431
  Complete submission text file 0001387131-22-000067.txt   198438

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20211231.xsd EX-101.SCH 3001
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20211231_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20211231_pre.xml EX-101.PRE 22343
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_123121_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 22506330
SIC: 2834 Pharmaceutical Preparations